Henry Schein, Inc.
HSIC Healthcare Medical Distribution
Henry Schein, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.2 billion, up 4.03% from fiscal 2024. In the quarter to June 2026, revenue grew 6.73%, EPS grew 16.9%, free cash flow grew 140.9% and total debt rose 15.2%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow HSIC
Henry Schein, Inc. (HSIC) Return on invested capital
Henry Schein, Inc.'s return on invested capital over the twelve months to 30 June 2026 was 6.97%, up 0.3 percentage points from fiscal 2025 (6.71%). Over the past ten years it has ranged from 6.19% (fiscal 2023) to 13.9% (fiscal 2015); the current reading is higher than 27% of that period. That is above the Medical Distribution industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 6.71% | 0.01 |
| FY2024 | 6.70% | 0.51 |
| FY2023 | 6.19% | (3.10) |
| FY2022 | 9.29% | (1.88) |
| FY2021 | 11.2% | 3.19 |
| FY2020 | 7.98% | (2.57) |
| FY2019 | 10.6% | 2.16 |
| FY2018 | 8.39% | (3.32) |
| FY2017 | 11.7% | (1.99) |
| FY2016 | 13.7% | (0.22) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| CAH Cardinal Health, Inc. compare | 125.1% |
| MCK McKesson Corporation compare | 70.5% |
| COR Cencora, Inc. compare | 15.7% |
| HSIC Henry Schein, Inc. | 6.97% |
| ACH Accendra Health, Inc. compare | 1.58% |
| AHG Akso Health Group Sponsored ADR compare | 0.00% |
| HKPD Cellyan Biotechnology Co., Ltd compare | 0.00% |
| COSM Cosmos Health Inc. compare | −38.2% |
| FOCL FocalTherics compare | −110.8% |
| Medical Distribution industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on HSIC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement